Recommended Conferences

Genetic Engineering and Gene Therapy

Paris, France

Human Genetics and Genetic Disorders

Miami, USA

Tissue Engineering and Regenerative Medicine

Chicago, USA
Related Subjects
 

Modelling the long QT syndrome with induced pluripotent stem cells

Author(s): Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, et al.

Abstract

The ability to generate patient-specific human induced pluripotent stem cells (iPSCs) offers a new paradigm for modelling human disease and for individualizing drug testing. Congenital long QT syndrome (LQTS) is a familial arrhythmogenic syndrome characterized by abnormal ion channel function and sudden cardiac death. Here we report the development of a patient/disease-specific human iPSC line from a patient with type-2 LQTS (which is due to the A614V missense mutation in the KCNH2 gene). The generated iPSCs were coaxed to differentiate into the cardiac lineage. Detailed whole-cell patch-clamp and extracellular multielectrode recordings revealed significant prolongation of the action-potential duration in LQTS human iPSC-derived cardiomyocytes (the characteristic LQTS phenotype) when compared to healthy control cells. Voltage-clamp studies confirmed that this action-potential-duration prolongation stems from a significant reduction of the cardiac potassium current I(Kr). Importantly, LQTS-derived cells also showed marked arrhythmogenicity, characterized by early-after depolarizations and triggered arrhythmias. We then used the LQTS human iPSC-derived cardiac-tissue model to evaluate the potency of existing and novel pharmacological agents that may either aggravate (potassium-channel blockers) or ameliorate (calcium-channel blockers, K(ATP)-channel openers and late sodium-channel blockers) the disease phenotype. Our study illustrates the ability of human iPSC technology to model the abnormal functional phenotype of an inherited cardiac disorder and to identify potential new therapeutic agents. As such, it represents a promising paradigm to study disease mechanisms, optimize patient care (personalized medicine), and aid in the development of new therapies.

Similar Articles

Naive and primed pluripotent states

Author(s): Nichols J, Smith A

MicroRNAs: key regulators of stem cells

Author(s): Gangaraju VK, Lin H

Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse

Author(s): Stadtfeld M, Maherali N, Breault DT, Hochedlinger K

Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells

Author(s): Chan EM, Ratanasirintrawoot S, Park IH, Manos PD, Loh YH, et al.

Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution

Author(s): Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, et al.

Epigenetic memory in induced pluripotent stem cells

Author(s): Kim K, Doi A, Wen B, Ng K, Zhao R, et al.

Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells

Author(s): Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, et al.

Immunogenicity of induced pluripotent stem cells

Author(s): Zhao T, Zhang ZN, Rong Z, Xu Y

Nuclear transfer to eggs and oocytes

Author(s): Gurdon JB, Wilmut I

CAF-1 is essential for heterochromatin organization in pluripotent embryonic cells

Author(s): Houlard M, Berlivet S, Probst AV, Quivy JP, Héry P, et al.

Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein

Author(s): Pivot-Pajot C, Caron C, Govin J, Vion A, Rousseaux S, et al.

Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors

Author(s): Jude CD, Climer L, Xu D, Artinger E, Fisher JK, et al.

Histone H4-K16 acetylation controls chromatin structure and protein interactions

Author(s): Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, et al.

Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs

Author(s): Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, et al.

Patient-specific induced pluripotent stem-cell models for long-QT syndrome

Author(s): Moretti A, Bellin M, Welling A, Jung CB, Lam JT, et al.